Benjamin Machinas Beneski - Mar 1, 2025 Form 3 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
SVP, Chief Technical Officer
Signature
/s/Earl Douglas, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Mar 1, 2025
Transactions value $
$0
Form type
3
Date filed
3/4/2025, 09:58 PM
Next filing
Mar 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ALLO Common Stock 192K Mar 1, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ALLO Stock Option (Right to buy) Mar 1, 2025 Common Stock 43.7K $1.94 Direct F1
holding ALLO Stock Option (Right to buy) Mar 1, 2025 Common Stock 24.4K $5.04 Direct F2
holding ALLO Stock Option (Right to buy) Mar 1, 2025 Common Stock 54.3K $13.31 Direct F3
holding ALLO Stock Option (Right to buy) Mar 1, 2025 Common Stock 9.01K $9.69 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F3 1/3rd of the shares subject to the option vest on each anniversary measured from July 19th, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
F4 25% of the shares subject to the stock option shall vest on March 13, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Remarks:

Exhibits: Power of Attorney